Oct 28, 2021
RNS Number : 6206Q MaxCyte, Inc. 28 October 2021             MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs   Nkarta to use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform to accelerate the development of its oncology
Oct 26, 2021
RNS Number : 2022Q MaxCyte, Inc. 26 October 2021   MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021   GAITHERSBURG, MD , October 26, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling
Oct 06, 2021
RNS Number : 1277O MaxCyte, Inc. 06 October 2021   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name   MAXCYTE, INC.   UK or Non- UK Issuer Non- UK   2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or
Oct 01, 2021
RNS Number : 8000N MaxCyte, Inc. 01 October 2021     MaxCyte, Inc. (" MaxCyte " or the "Company") Notice of Annual General Meeting   Change of Director   Gaithersburg, Maryland - 1 October 2021 :       MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company
Oct 01, 2021
RNS Number : 7698N MaxCyte, Inc. 01 October 2021     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 October 2021 :       MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company focused on providing enabling
Sep 17, 2021
RNS Number : 1652M MaxCyte, Inc. 17 September 2021   MaxCyte Set to Join Russell 2000® Index GAITHERSBURG, MD , September 16, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
Sep 17, 2021
GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
Sep 14, 2021
RNS Number : 6380L MaxCyte, Inc. 14 September 2021         MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections   GAITHERSBURG, MD , September 13, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell
Displaying 11 - 20 of 67